COLLEGIUM PHARMACEUTICAL, INC
About COLLEGIUM PHARMACEUTICAL, INC
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $780.6M
- Net income
- $62.9M
- Total assets
- $1.7B
- Market cap
- $1.1B
- Gross margin
- 59.3%
- Operating margin
- 23.0%
- Net margin
- 8.1%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $780.6M
- Cost of revenue
- $317.3M
- Gross profit
- $463.3M
- Operating expenses
- $283.6M
- Operating income
- $179.6M
- Income tax
- $29.7M
- Net income
- $62.9M
- EPS (basic)
- $1.98
- EPS (diluted)
- $1.73
Balance sheet
- Total assets
- $1.7B
- Current assets
- $691.4M
- Total liabilities
- $1.4B
- Current liabilities
- $440.0M
- Shareholders’ equity
- $301.7M
Cash flow
- Operating cash flow
- $329.3M
- Investing cash flow
- -$63.5M
- Financing cash flow
- -$110.2M
- Net cash flow
- $155.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.1B
- P/E ratio
- 19.2
- EPS (diluted)
- $1.73
- Shares outstanding
- 32.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 7, 2015
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $62.9M in FY2025.
- Revenue grew 152% from FY2020 to FY2025.
- Gross margin of 59.3%, net margin 8.1%.
- Trading 33% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 19.2.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review COLLEGIUM PHARMACEUTICAL, INC.
Write a review
News about COLLEGIUM PHARMACEUTICAL, INC
News & sentiment via Polygon.io
